WP4 will establish a data-sharing platform that will effectively exploit the data that has been pulled from multiple sources. This platform will provide descriptive and predictive information on seven types of HMs, thus improving decision-making and the treatment of patients. The creation of statistical models will identify the best practices that will enable the best evidence to be generated. WP4 will use the most innovative methods of data analysis and the most advanced algorithms in order to achieve the optimum management and mining of the data that has been collected.
Bayer, Celgene, EBMT, ELN, EORTC, GMV, HULAFE, IBSAL, Janssen, LeukaNET, MediUni Wien, Menarini, Novartis, Takeda, Ulm University, UNIBO, University of York.